Skip to Content

Retaane Approval Status

  • FDA approved: No
  • Brand name: Retaane
  • Generic name: anecortave acetate
  • Dosage form: Depot Suspension
  • Company: Alcon
  • Treatment for: Macular Degeneration

Retaane (anecortave) is an angiostatic cortisene that inhibits the abnormal growth of blood vessels. Retaane suspension is an investigational treatment for preserving the vision of patients with wet age-related macular degeneration (AMD).

Development Status and FDA Approval Process for Retaane

DateArticle
Sep 25, 2007Alcon Receives FDA Decision on Retaane Suspension for Wet AMD
May 24, 2005Alcon Receives Approvable Letter from FDA for Retaane Suspension
Dec 16, 2004Alcon Submits Retaane - Drug Applications to U.S. and European Regulatory Authorities
Jun 30, 2004Alcon Updates Filing Status of Retaane New Drug Application

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide